Clinical trial · no report yet · Phase 3

NCT07183189

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

NCT07183189 ↗
Active, not recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Focused

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Preliminary discovery

Commentary in our index that names this trial so far

Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.

Channel	Found
X threads	2
Bluesky threads	1

The trial

ClinicalTrials.gov

Official title: A Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib as First-line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations
Phase: Phase 3
Status: Active, not recruiting
Conditions: Non-small Cell Lung Cancer
Interventions: SHR-A2009 ; Aumolertinib; Aumolertinib
Arms: investigational treatment group：SHR-A2009 combined with Aumolertinib · Experimental
control group ：Aumolertinib · Active comparator
Enrollment: 582
Primary outcomes: Progression-free survival (PFS) assessed by BICR according to RECIST v1.1
Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Start: Oct 30, 2025
Primary completion: Nov 2032 (estimated)
Results posted: No
Registry record: NCT07183189 · updated Sep 25, 2026